IFNG and neoplasm: CRISPR/Cas9 technology has been applied by Pomeroy and colleagues to knock out the ADAM17 cleavage sequence in PB-NK cells, which led to upregulation of IFN-γ production and ADCC in a PD-1 knockout combined in vitro study including tumor-targeting mAbs [58,63].